Comparison of Insulin glargine 300 U/ml + SGLT2 inhibitor therapy (Tofogliflozin 20 mg vs. Ipragliflozin 50 mg) using continuous glucose monitoring (CGM): randomised crossover study
Not Applicable
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000023972
- Lead Sponsor
- General Inuyamachuo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
severe renal dysfunction (serum creatinine level over 2.0 mg/dL) judged to be unsuitable for participation for medical reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CGM AOC (70 mg/dL) for glycemic variability (0:00-6:00, 24:00) day2 day14
- Secondary Outcome Measures
Name Time Method M-value (0:00-6:00, 24:00, 8:00-24:00) MAGE MODD ADRR mean glucose level (0:00-6:00, 24:00, 8:00-24:00) SD (0:00-6:00, 24:00, 8:00-24:00) Highest postprandial glucose level within 3 hours after each meal Time from start of meal to the highest postprandial glucose level Differences between preprandial and highest postprandial glucose level for each meal post-breakfast glucose gradient AUC (140 mg/dL) for glycemic variability within 3 h of each meal AUC (0 mg/dL) for glycemic variability in 24 h